Impact of extraskeletal metastases on skeletal-related events in metastatic castration-resistant prostate cancer with bone metastases

Detalhes bibliográficos
Autor(a) principal: Lobo-Martins, Soraia
Data de Publicação: 2020
Outros Autores: Ferreira, Arlindo, Mansinho, André, Casimiro, Sandra, Leitzel, Kim, Ali, Suhail, Lipton, Allan, Costa, Luis
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10451/54570
Resumo: © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
id RCAP_557238e3e1d21a7b8c0975a5247d071a
oai_identifier_str oai:repositorio.ul.pt:10451/54570
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Impact of extraskeletal metastases on skeletal-related events in metastatic castration-resistant prostate cancer with bone metastasesBone metastasesBone-targeted agentsMetastatic castration-resistant prostate cancerProstate cancerVisceral metastases© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) has substantially evolved over the last decade. Nonetheless, a better understanding of bone-targeted agents (BTAs) action in mCRPC remains an unmet need. Theuse of BTAs aims to reduce the incidence of skeletal-related events (SREs) in patients with mCRPC. Less frequent BTA schedules are currently being studied to minimize adverse events. In this study, the impact of metastatic compartment (bone and extraskeletal metastases (BESM) vs. bone-only metastases (BOM)) on bone biomarker kinetics, time to first on-study SRE, and symptomatic skeletal events (SSEs) is evaluated. This is a retrospective analysis of the prospective, randomized, multicenter clinical trial of denosumab vs. zoledronic acid in patients with mCRPC and bone metastases. A total of 1901 patients were included, 1559 (82.0%) with BOM and 342 with BESM (18.0%). Bone metastases burden was balanced between groups. Baseline levels and normalization rates of corrected urinary N-terminal telopeptide and bone alkaline phosphatase did not differ between groups. However, BESM patients had a higher risk of SREs (adjusted HR 1.21; 95% CI 1.01-1.46; p = 0.043) and SSEs (adjusted HR 1.30; 95% CI 1.06-1.61; p = 0.014). This difference was more pronounced in the first 12 months of BTA treatment.In mCRPC, strategies of BTA schedule de-escalation may take into account presence of extraskeletal metastases.MDPIRepositório da Universidade de LisboaLobo-Martins, SoraiaFerreira, ArlindoMansinho, AndréCasimiro, SandraLeitzel, KimAli, SuhailLipton, AllanCosta, Luis2022-09-23T13:45:48Z20202020-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/54570engCancers (Basel). 2020 Jul 24;12(8):203410.3390/cancers120820342072-6694info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-08T17:01:01Zoai:repositorio.ul.pt:10451/54570Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T22:05:22.946313Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Impact of extraskeletal metastases on skeletal-related events in metastatic castration-resistant prostate cancer with bone metastases
title Impact of extraskeletal metastases on skeletal-related events in metastatic castration-resistant prostate cancer with bone metastases
spellingShingle Impact of extraskeletal metastases on skeletal-related events in metastatic castration-resistant prostate cancer with bone metastases
Lobo-Martins, Soraia
Bone metastases
Bone-targeted agents
Metastatic castration-resistant prostate cancer
Prostate cancer
Visceral metastases
title_short Impact of extraskeletal metastases on skeletal-related events in metastatic castration-resistant prostate cancer with bone metastases
title_full Impact of extraskeletal metastases on skeletal-related events in metastatic castration-resistant prostate cancer with bone metastases
title_fullStr Impact of extraskeletal metastases on skeletal-related events in metastatic castration-resistant prostate cancer with bone metastases
title_full_unstemmed Impact of extraskeletal metastases on skeletal-related events in metastatic castration-resistant prostate cancer with bone metastases
title_sort Impact of extraskeletal metastases on skeletal-related events in metastatic castration-resistant prostate cancer with bone metastases
author Lobo-Martins, Soraia
author_facet Lobo-Martins, Soraia
Ferreira, Arlindo
Mansinho, André
Casimiro, Sandra
Leitzel, Kim
Ali, Suhail
Lipton, Allan
Costa, Luis
author_role author
author2 Ferreira, Arlindo
Mansinho, André
Casimiro, Sandra
Leitzel, Kim
Ali, Suhail
Lipton, Allan
Costa, Luis
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório da Universidade de Lisboa
dc.contributor.author.fl_str_mv Lobo-Martins, Soraia
Ferreira, Arlindo
Mansinho, André
Casimiro, Sandra
Leitzel, Kim
Ali, Suhail
Lipton, Allan
Costa, Luis
dc.subject.por.fl_str_mv Bone metastases
Bone-targeted agents
Metastatic castration-resistant prostate cancer
Prostate cancer
Visceral metastases
topic Bone metastases
Bone-targeted agents
Metastatic castration-resistant prostate cancer
Prostate cancer
Visceral metastases
description © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
publishDate 2020
dc.date.none.fl_str_mv 2020
2020-01-01T00:00:00Z
2022-09-23T13:45:48Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10451/54570
url http://hdl.handle.net/10451/54570
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Cancers (Basel). 2020 Jul 24;12(8):2034
10.3390/cancers12082034
2072-6694
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134605303873536

Registros relacionados